Oxidation Products of Uric Acid and Ascorbic Acid in Preterm Infants with Chronic Lung Disease
Allantoin, the oxidation product of uric acid (UA), can be used as an in vivo marker of free radical generation. The aims of the present study were to evaluate the allantoin changes in plasma and bronchoalveolar lavage fluid (BALF) as well as to examine plasma levels of ascorbic acid (AA) and its ox...
Gespeichert in:
| Veröffentlicht in: | Biology of the neonate 1998-01, Vol.73 (1), p.24-33 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 33 |
|---|---|
| container_issue | 1 |
| container_start_page | 24 |
| container_title | Biology of the neonate |
| container_volume | 73 |
| creator | Ogihara, Tohru Kim, Han-Suk Hirano, Kazuya Imanishi, Miho Ogihara, Hiromi Tamai, Hiroshi Okamoto, Ryozo Mino, Makoto |
| description | Allantoin, the oxidation product of uric acid (UA), can be used as an in vivo marker of free radical generation. The aims of the present study were to evaluate the allantoin changes in plasma and bronchoalveolar lavage fluid (BALF) as well as to examine plasma levels of ascorbic acid (AA) and its oxidation product, dehydroascorbic acid (DHAA), in infants with or without chronic lung disease (CLD) during the first week of life. The study population was 20 infants of 24–30 weeks gestation, comprising 10 who subsequently developed CLD and 10 without CLD. In the CLD infants, the plasma allantoin/UA ratio showed a significant increase after day 1 and continued to increase gradually to reach a peak on day 6 (6.5 ± 4.1% for CLD and 2.1 ± 0.9% for non-CLD infants). The allantoin/UA ratio in BALF was also higher in CLD infants and the difference reached significance on days 4–6 (41.2 ± 15.8% for CLD and 11.7 ± 9.9% for non-CLD infants). In contrast to allantoin, the plasma DHAA/AA ratio did not differ between the 2 groups throughout the study period. Our findings that the allantoin/UA ratios were significantly higher in CLD than non-CLD infants not only in plasma but also in BALF, and that the intergroup differences of this ratio in both plasma and BALF was more prominent in the latter half of the first week of life further confirm our previous speculation that oxygen radicals are involved in the development of neonatal CLD. |
| doi_str_mv | 10.1159/000013956 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1159_000013956</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>668196891</sourcerecordid><originalsourceid>FETCH-LOGICAL-c383t-7426c807e55c6e34425ddc12f74e90250be31b0ad8da8570f4d808d5425ac8ea3</originalsourceid><addsrcrecordid>eNpt0MtOAyEUBmBiNFovC9fGhBhj4qIKzMDAstZr0lgXunVCgWmpLVSYifr2oh1rYmQD4f84hxwA9jE6w5iKc5QWzgRla6CDGcPdgmOxvjojtAW2Y5wiRCllZBNsipxykYkOeB6-Wy1r6x18CF43qo7QV_ApWAV7ymoonYa9qHwY_dzYL2pqE-bwzlXSpRdvtp7A_iR4l9CgcWN4aaOR0eyCjUrOotlr9x3wdH312L_tDoY3d_3eoKsyntXdIidMcVQYShUzWZ4TqrXCpCpyIxChaGQyPEJScy05LVCVa464pslJxY3MdsDJsu4i-NfGxLqc26jMbCad8U0sC8EKzghP8OgPnPomuPS3khBS0FwwktDpEqngYwymKhfBzmX4KDEqvwZergae7GFbsBnNjV7JdsIpP25zGZWcVUE6ZeOKESRwqpLYwZK9yDA24bdh2-To3_RieP8NyoWusk-6m5n2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222754962</pqid></control><display><type>article</type><title>Oxidation Products of Uric Acid and Ascorbic Acid in Preterm Infants with Chronic Lung Disease</title><source>MEDLINE</source><source>Karger Journals</source><creator>Ogihara, Tohru ; Kim, Han-Suk ; Hirano, Kazuya ; Imanishi, Miho ; Ogihara, Hiromi ; Tamai, Hiroshi ; Okamoto, Ryozo ; Mino, Makoto</creator><creatorcontrib>Ogihara, Tohru ; Kim, Han-Suk ; Hirano, Kazuya ; Imanishi, Miho ; Ogihara, Hiromi ; Tamai, Hiroshi ; Okamoto, Ryozo ; Mino, Makoto</creatorcontrib><description>Allantoin, the oxidation product of uric acid (UA), can be used as an in vivo marker of free radical generation. The aims of the present study were to evaluate the allantoin changes in plasma and bronchoalveolar lavage fluid (BALF) as well as to examine plasma levels of ascorbic acid (AA) and its oxidation product, dehydroascorbic acid (DHAA), in infants with or without chronic lung disease (CLD) during the first week of life. The study population was 20 infants of 24–30 weeks gestation, comprising 10 who subsequently developed CLD and 10 without CLD. In the CLD infants, the plasma allantoin/UA ratio showed a significant increase after day 1 and continued to increase gradually to reach a peak on day 6 (6.5 ± 4.1% for CLD and 2.1 ± 0.9% for non-CLD infants). The allantoin/UA ratio in BALF was also higher in CLD infants and the difference reached significance on days 4–6 (41.2 ± 15.8% for CLD and 11.7 ± 9.9% for non-CLD infants). In contrast to allantoin, the plasma DHAA/AA ratio did not differ between the 2 groups throughout the study period. Our findings that the allantoin/UA ratios were significantly higher in CLD than non-CLD infants not only in plasma but also in BALF, and that the intergroup differences of this ratio in both plasma and BALF was more prominent in the latter half of the first week of life further confirm our previous speculation that oxygen radicals are involved in the development of neonatal CLD.</description><identifier>ISSN: 1661-7800</identifier><identifier>ISSN: 0006-3126</identifier><identifier>EISSN: 1661-7819</identifier><identifier>EISSN: 1421-9727</identifier><identifier>DOI: 10.1159/000013956</identifier><identifier>PMID: 9458939</identifier><identifier>CODEN: BNEOBV</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Allantoin - analysis ; Allantoin - blood ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Ascorbic Acid - blood ; Ascorbic Acid - chemistry ; Ascorbic Acid - metabolism ; Biological and medical sciences ; Biomarkers - analysis ; Biomarkers - blood ; Bronchoalveolar Lavage Fluid - chemistry ; Chronic Disease ; Cohort Studies ; Dehydroascorbic Acid - blood ; Emergency and intensive care: neonates and children. Prematurity. Sudden death ; Female ; Free Radicals ; Humans ; Infant, Newborn ; Infant, Premature, Diseases - blood ; Infant, Premature, Diseases - metabolism ; Intensive care medicine ; Lung Diseases - blood ; Lung Diseases - metabolism ; Male ; Medical sciences ; Original Paper ; Oxidation-Reduction ; Uric Acid - blood ; Uric Acid - chemistry ; Uric Acid - metabolism</subject><ispartof>Biology of the neonate, 1998-01, Vol.73 (1), p.24-33</ispartof><rights>1998 S. Karger AG, Basel</rights><rights>1998 INIST-CNRS</rights><rights>Copyright (c) 1998 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c383t-7426c807e55c6e34425ddc12f74e90250be31b0ad8da8570f4d808d5425ac8ea3</citedby><cites>FETCH-LOGICAL-c383t-7426c807e55c6e34425ddc12f74e90250be31b0ad8da8570f4d808d5425ac8ea3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,2423,4010,27904,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2091563$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9458939$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ogihara, Tohru</creatorcontrib><creatorcontrib>Kim, Han-Suk</creatorcontrib><creatorcontrib>Hirano, Kazuya</creatorcontrib><creatorcontrib>Imanishi, Miho</creatorcontrib><creatorcontrib>Ogihara, Hiromi</creatorcontrib><creatorcontrib>Tamai, Hiroshi</creatorcontrib><creatorcontrib>Okamoto, Ryozo</creatorcontrib><creatorcontrib>Mino, Makoto</creatorcontrib><title>Oxidation Products of Uric Acid and Ascorbic Acid in Preterm Infants with Chronic Lung Disease</title><title>Biology of the neonate</title><addtitle>Neonatology</addtitle><description>Allantoin, the oxidation product of uric acid (UA), can be used as an in vivo marker of free radical generation. The aims of the present study were to evaluate the allantoin changes in plasma and bronchoalveolar lavage fluid (BALF) as well as to examine plasma levels of ascorbic acid (AA) and its oxidation product, dehydroascorbic acid (DHAA), in infants with or without chronic lung disease (CLD) during the first week of life. The study population was 20 infants of 24–30 weeks gestation, comprising 10 who subsequently developed CLD and 10 without CLD. In the CLD infants, the plasma allantoin/UA ratio showed a significant increase after day 1 and continued to increase gradually to reach a peak on day 6 (6.5 ± 4.1% for CLD and 2.1 ± 0.9% for non-CLD infants). The allantoin/UA ratio in BALF was also higher in CLD infants and the difference reached significance on days 4–6 (41.2 ± 15.8% for CLD and 11.7 ± 9.9% for non-CLD infants). In contrast to allantoin, the plasma DHAA/AA ratio did not differ between the 2 groups throughout the study period. Our findings that the allantoin/UA ratios were significantly higher in CLD than non-CLD infants not only in plasma but also in BALF, and that the intergroup differences of this ratio in both plasma and BALF was more prominent in the latter half of the first week of life further confirm our previous speculation that oxygen radicals are involved in the development of neonatal CLD.</description><subject>Allantoin - analysis</subject><subject>Allantoin - blood</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Ascorbic Acid - blood</subject><subject>Ascorbic Acid - chemistry</subject><subject>Ascorbic Acid - metabolism</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - analysis</subject><subject>Biomarkers - blood</subject><subject>Bronchoalveolar Lavage Fluid - chemistry</subject><subject>Chronic Disease</subject><subject>Cohort Studies</subject><subject>Dehydroascorbic Acid - blood</subject><subject>Emergency and intensive care: neonates and children. Prematurity. Sudden death</subject><subject>Female</subject><subject>Free Radicals</subject><subject>Humans</subject><subject>Infant, Newborn</subject><subject>Infant, Premature, Diseases - blood</subject><subject>Infant, Premature, Diseases - metabolism</subject><subject>Intensive care medicine</subject><subject>Lung Diseases - blood</subject><subject>Lung Diseases - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Original Paper</subject><subject>Oxidation-Reduction</subject><subject>Uric Acid - blood</subject><subject>Uric Acid - chemistry</subject><subject>Uric Acid - metabolism</subject><issn>1661-7800</issn><issn>0006-3126</issn><issn>1661-7819</issn><issn>1421-9727</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0MtOAyEUBmBiNFovC9fGhBhj4qIKzMDAstZr0lgXunVCgWmpLVSYifr2oh1rYmQD4f84hxwA9jE6w5iKc5QWzgRla6CDGcPdgmOxvjojtAW2Y5wiRCllZBNsipxykYkOeB6-Wy1r6x18CF43qo7QV_ApWAV7ymoonYa9qHwY_dzYL2pqE-bwzlXSpRdvtp7A_iR4l9CgcWN4aaOR0eyCjUrOotlr9x3wdH312L_tDoY3d_3eoKsyntXdIidMcVQYShUzWZ4TqrXCpCpyIxChaGQyPEJScy05LVCVa464pslJxY3MdsDJsu4i-NfGxLqc26jMbCad8U0sC8EKzghP8OgPnPomuPS3khBS0FwwktDpEqngYwymKhfBzmX4KDEqvwZergae7GFbsBnNjV7JdsIpP25zGZWcVUE6ZeOKESRwqpLYwZK9yDA24bdh2-To3_RieP8NyoWusk-6m5n2</recordid><startdate>199801</startdate><enddate>199801</enddate><creator>Ogihara, Tohru</creator><creator>Kim, Han-Suk</creator><creator>Hirano, Kazuya</creator><creator>Imanishi, Miho</creator><creator>Ogihara, Hiromi</creator><creator>Tamai, Hiroshi</creator><creator>Okamoto, Ryozo</creator><creator>Mino, Makoto</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>199801</creationdate><title>Oxidation Products of Uric Acid and Ascorbic Acid in Preterm Infants with Chronic Lung Disease</title><author>Ogihara, Tohru ; Kim, Han-Suk ; Hirano, Kazuya ; Imanishi, Miho ; Ogihara, Hiromi ; Tamai, Hiroshi ; Okamoto, Ryozo ; Mino, Makoto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c383t-7426c807e55c6e34425ddc12f74e90250be31b0ad8da8570f4d808d5425ac8ea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Allantoin - analysis</topic><topic>Allantoin - blood</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Ascorbic Acid - blood</topic><topic>Ascorbic Acid - chemistry</topic><topic>Ascorbic Acid - metabolism</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - analysis</topic><topic>Biomarkers - blood</topic><topic>Bronchoalveolar Lavage Fluid - chemistry</topic><topic>Chronic Disease</topic><topic>Cohort Studies</topic><topic>Dehydroascorbic Acid - blood</topic><topic>Emergency and intensive care: neonates and children. Prematurity. Sudden death</topic><topic>Female</topic><topic>Free Radicals</topic><topic>Humans</topic><topic>Infant, Newborn</topic><topic>Infant, Premature, Diseases - blood</topic><topic>Infant, Premature, Diseases - metabolism</topic><topic>Intensive care medicine</topic><topic>Lung Diseases - blood</topic><topic>Lung Diseases - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Original Paper</topic><topic>Oxidation-Reduction</topic><topic>Uric Acid - blood</topic><topic>Uric Acid - chemistry</topic><topic>Uric Acid - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ogihara, Tohru</creatorcontrib><creatorcontrib>Kim, Han-Suk</creatorcontrib><creatorcontrib>Hirano, Kazuya</creatorcontrib><creatorcontrib>Imanishi, Miho</creatorcontrib><creatorcontrib>Ogihara, Hiromi</creatorcontrib><creatorcontrib>Tamai, Hiroshi</creatorcontrib><creatorcontrib>Okamoto, Ryozo</creatorcontrib><creatorcontrib>Mino, Makoto</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Biology of the neonate</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ogihara, Tohru</au><au>Kim, Han-Suk</au><au>Hirano, Kazuya</au><au>Imanishi, Miho</au><au>Ogihara, Hiromi</au><au>Tamai, Hiroshi</au><au>Okamoto, Ryozo</au><au>Mino, Makoto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oxidation Products of Uric Acid and Ascorbic Acid in Preterm Infants with Chronic Lung Disease</atitle><jtitle>Biology of the neonate</jtitle><addtitle>Neonatology</addtitle><date>1998-01</date><risdate>1998</risdate><volume>73</volume><issue>1</issue><spage>24</spage><epage>33</epage><pages>24-33</pages><issn>1661-7800</issn><issn>0006-3126</issn><eissn>1661-7819</eissn><eissn>1421-9727</eissn><coden>BNEOBV</coden><abstract>Allantoin, the oxidation product of uric acid (UA), can be used as an in vivo marker of free radical generation. The aims of the present study were to evaluate the allantoin changes in plasma and bronchoalveolar lavage fluid (BALF) as well as to examine plasma levels of ascorbic acid (AA) and its oxidation product, dehydroascorbic acid (DHAA), in infants with or without chronic lung disease (CLD) during the first week of life. The study population was 20 infants of 24–30 weeks gestation, comprising 10 who subsequently developed CLD and 10 without CLD. In the CLD infants, the plasma allantoin/UA ratio showed a significant increase after day 1 and continued to increase gradually to reach a peak on day 6 (6.5 ± 4.1% for CLD and 2.1 ± 0.9% for non-CLD infants). The allantoin/UA ratio in BALF was also higher in CLD infants and the difference reached significance on days 4–6 (41.2 ± 15.8% for CLD and 11.7 ± 9.9% for non-CLD infants). In contrast to allantoin, the plasma DHAA/AA ratio did not differ between the 2 groups throughout the study period. Our findings that the allantoin/UA ratios were significantly higher in CLD than non-CLD infants not only in plasma but also in BALF, and that the intergroup differences of this ratio in both plasma and BALF was more prominent in the latter half of the first week of life further confirm our previous speculation that oxygen radicals are involved in the development of neonatal CLD.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>9458939</pmid><doi>10.1159/000013956</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1661-7800 |
| ispartof | Biology of the neonate, 1998-01, Vol.73 (1), p.24-33 |
| issn | 1661-7800 0006-3126 1661-7819 1421-9727 |
| language | eng |
| recordid | cdi_crossref_primary_10_1159_000013956 |
| source | MEDLINE; Karger Journals |
| subjects | Allantoin - analysis Allantoin - blood Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Ascorbic Acid - blood Ascorbic Acid - chemistry Ascorbic Acid - metabolism Biological and medical sciences Biomarkers - analysis Biomarkers - blood Bronchoalveolar Lavage Fluid - chemistry Chronic Disease Cohort Studies Dehydroascorbic Acid - blood Emergency and intensive care: neonates and children. Prematurity. Sudden death Female Free Radicals Humans Infant, Newborn Infant, Premature, Diseases - blood Infant, Premature, Diseases - metabolism Intensive care medicine Lung Diseases - blood Lung Diseases - metabolism Male Medical sciences Original Paper Oxidation-Reduction Uric Acid - blood Uric Acid - chemistry Uric Acid - metabolism |
| title | Oxidation Products of Uric Acid and Ascorbic Acid in Preterm Infants with Chronic Lung Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T02%3A39%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oxidation%20Products%20of%20Uric%20Acid%20and%20Ascorbic%20Acid%20in%20Preterm%20Infants%20with%20Chronic%20Lung%20Disease&rft.jtitle=Biology%20of%20the%20neonate&rft.au=Ogihara,%20Tohru&rft.date=1998-01&rft.volume=73&rft.issue=1&rft.spage=24&rft.epage=33&rft.pages=24-33&rft.issn=1661-7800&rft.eissn=1661-7819&rft.coden=BNEOBV&rft_id=info:doi/10.1159/000013956&rft_dat=%3Cproquest_cross%3E668196891%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=222754962&rft_id=info:pmid/9458939&rfr_iscdi=true |